HC Wainwright & Co. Reiterates Buy on RAPT Therapeutics, Maintains $41 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on RAPT Therapeutics (NASDAQ:RAPT) and maintained a $41 price target.
June 05, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RAPT Therapeutics receives a reiterated Buy rating from HC Wainwright & Co. analyst Raghuram Selvaraju, with a maintained $41 price target.
The reiterated Buy rating and maintained $41 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for RAPT Therapeutics. This news is likely to have a positive short-term impact on the stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100